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ABSTRACT 
 
Sudden cardiac death (SCD) is the leading cause of mortality in athletes during sport. A variety 
of mostly hereditary, structural or electrical cardiac disorders are associated with SCD in young 
athletes, the majority of which can be identified or suggested by abnormalities on a resting 12-
lead electrocardiogram (ECG). Whether used for diagnostic or screening purposes, physicians 
responsible for the cardiovascular care of athletes should be knowledgeable and competent in 
ECG interpretation in athletes. However, in most countries a shortage of physician expertise 
limits wider application of the ECG in the care of the athlete. A critical need exists for physician 
education in modern ECG interpretation that distinguishes normal physiological adaptations in 
athletes from distinctly abnormal findings suggestive of underlying pathology. Since the original 
2010 European Society of Cardiology recommendations for ECG interpretation in athletes, ECG 
standards have evolved quickly over the last decade; pushed by a growing body of scientific data 
that both tests proposed criteria sets and establishes new evidence to guide refinements. On 
February 26-27, 2015, an international group of experts in sports cardiology, inherited cardiac 
disease, and sports medicine convened in Seattle, Washington, to update contemporary standards 
for ECG interpretation in athletes. The objective of the meeting was to define and revise ECG 
interpretation standards based on new and emerging research and to develop a clear guide to the 
proper evaluation of ECG abnormalities in athletes. This statement represents an international 
consensus for ECG interpretation in athletes and provides expert opinion-based 
recommendations linking specific ECG abnormalities and the secondary evaluation for 
conditions associated with SCD.  
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INTRODUCTION 
 
Cardiovascular-related sudden death is the leading cause of mortality in athletes during sport and 
exercise.1-3 The majority of disorders associated with an increased risk of sudden cardiac death 
(SCD), such as cardiomyopathies and primary electrical diseases (channelopathies), are 
suggested or identified by abnormalities present on a resting 12-lead ECG. Interpretation of an 
ECG in athletes requires careful analysis to properly distinguish physiological changes related to 
athletic training from findings suggestive of an underlying pathological condition. Whether used 
for the evaluation of cardiovascular-related symptoms, a family history of inheritable cardiac 
disease or premature SCD, or for screening of asymptomatic athletes, ECG interpretation is an 
essential skill for all physicians involved in the cardiovascular care of athletes.    
 
The 2015 Summit on ECG Interpretation in Athletes 
  
On February 26-27, 2015, an international group of experts in sports cardiology, inherited 
cardiac diseases, and sports medicine convened in Seattle, Washington, to update contemporary 
standards for ECG interpretation in athletes through development of an “international 
consensus”. This summit meeting served as the critical foundation for subsequent work done by 
the larger writing group that ultimately generated this document. The goals of the summit 
meeting were to: 1) update ECG interpretation standards based on new and emerging research; 
and 2) develop a clear guide to the appropriate evaluation of ECG abnormalities for conditions 
associated with SCD in athletes.   
 
The standards presented were developed with consideration of ECG interpretation in the context 
of an asymptomatic athlete aged 12-35 years. An athlete is defined as an individual who engages 
in regular exercise or training for sport or general fitness, typically with a premium on 
performance, and often engaged in individual or team competition. The prevalence of specific 
ECG findings in athletes may vary based on age, gender, ethnicity, type of sport and level of 
conditioning. Training-related physiological changes are more common in athletes exercising 
intensively at least 4-8 hours per week; thus prudent application of the criteria should occur in 
individuals at lower levels of regular exercise. Novel to these standards are specific 
considerations presented for young adolescent athletes age 12-16 years, as well as for older 
athletes ≥ 30 years where the prevalence of occult coronary artery disease (CAD) sharply 
increases. In the presence of cardiac symptoms or a family history of inherited cardiovascular 
disease or premature SCD, the interpretation standards may require modification.  
 
The recommendations presented in this statement were developed with thoughtful attention to 
balance sensitivity and specificity, while maintaining a clear and practical checklist of findings to 
guide ECG interpretation for physicians and the appropriate evaluation of ECG abnormalities. A 
summary of consensus recommendations from this panel is presented in Figure 1, Table 1, and 
Table 2. Physicians may choose to deviate from these consensus standards based on their 
experience or practice setting and according to the individual characteristics of the athlete. 
Ideally, the evaluation of ECG abnormalities is performed in consultation with a specialist with 
knowledge and experience in training-related cardiac adaptations and disorders associated with 
SCD in young athletes. 
 
5 
 
Distinguishing Normal from Abnormal 
 
A challenge in the interpretation of an athlete’s ECG is the ability to accurately differentiate 
findings suggestive of a potentially serious cardiovascular disorder from benign physiological 
adaptations occurring as the result of regular, intense training (i.e., athlete’s heart). Several 
reports have outlined contemporary ECG criteria intended to distinguish normal ECG findings in 
athletes from ECG abnormalities requiring additional evaluation.4-10  
 
Evolution of ECG Interpretation Standards 
 
Over the last decade, ECG interpretation standards have undergone several modifications to 
improve the accuracy of detecting potentially life threatening cardiac conditions in young 
athletes while also limiting false-positive results. In 2005, criteria for an abnormal ECG were 
defined by the Study Group of Sport Cardiology of the Working Group of Cardiac Rehabilitation 
and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the 
European Society of Cardiology (ESC).11 In 2010, driven by new research and large-population 
clinical investigations,12, 13 the ESC updated recommendations for interpretation of an athlete’s 
ECG in a landmark statement which pioneered “modern” ECG interpretation standards.5 The 
2010 ESC criteria were the first to divide ECG findings into two groups – common and training-
related (Group 1) versus uncommon and training-unrelated (Group 2) – based on the prevalence 
of ECG findings, relation to exercise training, and association with pathological conditions 
associated with SCD requiring further clinical investigation to confirm (or exclude) underlying 
cardiovascular disease.5 Since then, other investigators and international panels have proposed 
updated guidelines for ECG interpretation in young athletes.6, 9, 14 In 2012, leading sports 
medicine, inherited cardiac disease specialists, and sports cardiology physicians with expertise in 
the cardiovascular evaluation of young competitive athletes convened in Seattle, Washington, to 
redefine contemporary standards and develop an online training course 
(http://learning.bmj.com/ECGathlete) for ECG interpretation in athletes.10, 15-17  
 
Each revision of the ECG standards has demonstrated improved specificity while maintaining the 
sensitivity for ECG detectable pathological conditions associated with SCD. For example, in a 
study of 1,078 elite Australian athletes, the false-positive rate decreased from 17% using the 
2010 ESC criteria to 4.2% with the Seattle criteria, with no change in sensitivity.18 In another 
study of 2,017 high school athletes from the U.S., the Seattle criteria produced a low false-
positive rate (2.8%) with 100% sensitivity for SCD-associated conditions.19 In a study of 1,417 
high school, college, and professional athletes comparing three published ECG interpretation 
algorithms for athlete pre-participation screening, the proportion of abnormal ECGs declined 
from 26% to 8.1% to 5.7% using the ESC, Stanford, and Seattle criteria, respectively.20  
 
Recent research has directed additional revisions to ECG interpretation standards that further 
lower the false-positive rate.21, 22 The ‘refined’ criteria were investigated in an instrumental study 
examining 4,297 white and 1,208 black elite athletes, and 103 athletes diagnosed with 
hypertrophic cardiomyopathy (HCM).23 The total ECG abnormal rate declined dependent on the 
criteria applied – 21.5% (ESC), 9.6% (Seattle), and 6.6% (refined) – while all three criteria 
identified 98.1% of athletes with established HCM.23 Of the 5,505 athletes screened, 15 (0.47%) 
were diagnosed with conditions associated with SCD, including 5 cases of HCM, 5 cases of 
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Wolff-Parkinson-White (WPW), 3 cases of long QT syndrome (LQTS), and 1 case each of 
Brugada syndrome (BrS) and an anomalous coronary artery.23 Fourteen of 15 (93%) serious 
conditions were identified by ECG, and only one identified because of prior symptoms.23 In 
another study of 2,491 athletes undergoing pre-participation screening, application of the ESC, 
Seattle, and ‘refined’ criteria led to abnormal ECG rates of 22.3%, 11.6%, and 5.3%, 
respectively, all with 100% sensitivity for the pathological conditions detected.24  
 
Effective use of ECG in the cardiovascular care of athletes requires that abnormal findings 
receive appropriate secondary investigations to confirm or exclude conditions associated with 
SCD. However, the clinical response to abnormal ECG findings may vary based on physician 
training and experience. As a guide for clinicians, this document provides recommendations for 
the evaluation of specific ECG abnormalities.  
 
Limitations 
 
While ECG increases the ability to detect underlying cardiovascular conditions that place 
athletes at increased risk of SCD, ECG as a diagnostic tool has limitations in both sensitivity and 
specificity. Specifically, ECG can suggest or detect cardiomyopathies, ion channelopathies, 
myocarditis, and ventricular pre-excitation, yet other causes of SCD in young athletes such as 
anomalous coronary arteries, premature coronary atherosclerosis and aortopathies are not readily 
detected by ECG. Thus, even if properly interpreted, an ECG will not detect all conditions 
predisposing to SCD, and evaluation of cardiovascular symptoms, a concerning family history, 
or abnormal physical examination requires a more comprehensive investigation. 
 
An objective of developing ECG standards is to improve the accuracy and reproducibility of 
interpretation. Indeed, studies have demonstrated that systematic evaluation of an athlete’s ECG 
using standardized criteria improves interpretation accuracy among physicians across 
disciplines.14, 25 However, inter-observer variability and the reliability of ECG standards even 
among experienced physicians remains a major concern.26, 27 In one study, pediatric 
cardiologists, without use of a standardized criteria set, achieved a sensitivity of only 68% and a 
specificity of 70% for recognition of abnormal ECG patterns that occur infrequently but 
represent conditions causing SCD.28 In the future, the accuracy of ECG interpretation in athletes 
may be assisted by ECG devices using athlete-specific interpretation algorithms.  
 
The Importance of Proper Electrode Placement 
 
Misplacement of the limb leads can cause errors in axis measurement and pseudo-Q waves. 
Misplacement of the precordial electrodes downward can cause pseudo-Q waves and failure to 
detect ST segment depression. Upward misplacement of the precordial leads can simulate 
myocardial injury, pericarditis or the Brugada type 2 pattern, due to pseudo-ST segment 
elevation. Right and left arm lead reversal is recognized by negative P waves, a negative QRS 
complex, and T wave inversion (TWI) in leads I and aVL but not in the lateral precordial leads 
(V5-V6).   
 
Accurate placement of the precordial leads can be challenging. Leads V1, V2 and V4 have 
distinct bony landmarks for their placement that are critical for the placement of V3, V5 and V6. 
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V1 and V2 are close to the sternum in the 4th intercostal space (usually just above the nipple 
level). V4 is in the 5th intercostal space (usually just below the nipple line) and at the mid-
clavicular line. V3 is placed on a line between V2 and V4. V5 and V6 are on a horizontal plane 
set by V4 and do not curve along the interspace. They intersect with vertical lines established by 
the anterior axillary fold (V5) and the mid-point of the axilla (V6). 
 
 
NORMAL ECG FINDINGS IN ATHLETES 
 
Overview of Physiological Cardiac Adaptations to Regular Exercise  
 
Regular and long-term participation in intensive exercise (minimum of 4 hours per week) is 
associated with unique electrical manifestations that reflect enlarged cardiac chamber size and 
increased vagal tone. These ECG findings in athletes are considered normal, physiological 
adaptations to regular exercise and do not require further evaluation (Figure 1; Table 1). 
 
Increased Cardiac Chamber Size 
Voltage criterion for left ventricular hypertrophy (LVH) is observed commonly on an athlete’s 
ECG and thought to reflect a physiological increase in cardiac mass from athletic cardiac 
remodeling (Figure 2). Likewise, voltage criteria for right ventricular hypertrophy (RVH) and 
incomplete right bundle branch block (RBBB) are also common ECG findings in athletes and 
considered a result of increased right ventricular (RV) size secondary to regular training. 
 
Increased Vagal Tone 
Common consequences of increased vagal tone include early repolarization, sinus bradycardia, 
and sinus arrhythmia (Figure 2). Other, less common markers of increased vagal tone are 
junctional or ectopic atrial rhythms, first degree atrioventricular (AV) block, and Mobitz type I 
second degree AV block (Wenckebach phenomenon).   
 
QRS Voltage Criteria for Ventricular Hypertrophy 
 
Left Ventricular Hypertrophy 
QRS voltage can be influenced by a variety of factors, with male gender, athletic activity and 
younger age associated with higher QRS voltage, while obesity and pulmonary disease may 
cause lower voltage.29 All existing ECG criteria for LVH correlate poorly with increased left 
ventricular (LV) wall thickness and LV mass on imaging studies.30 Although there are several 
voltage criteria to define LVH, the Sokolow-Lyon criterion is used most commonly, defined as 
the sum of the S wave in V1 and the R wave in V5 or V6 (using the largest R wave) as > 3.5 mV 
(35 small squares with a standard amplification of the ECG at 10 mm/1 mV). Trained athletes 
often satisfy QRS voltage criterion for LVH, with up to 64% of athletes fulfilling the Sokolow-
Lyon index (Figure 2).31-36  
 
The presence of isolated QRS voltage criterion for LVH does not correlate with pathology in 
athletes and is present in isolation (without other associated ECG abnormalities) in less than 2% 
of patients with HCM.30-32, 37-40 Although clearance of athletes with isolated voltage criterion for 
LVH will fail to detect a very small minority of individuals with HCM, such individuals have a 
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milder phenotype with a low arrhythmogenic risk.40 Conversely, pathological LVH is commonly 
associated with additional ECG features such as TWI in the inferior and lateral leads, ST 
segment depression, and pathological Q waves (Figure 3).23, 41 Therefore, the isolated presence 
of high QRS voltages fulfilling voltage criterion for LVH in the absence of other ECG or clinical 
markers suggestive of pathology are considered part of the normal and training-related ECG 
changes in athletes related to physiological increases in cardiac chamber size and/or wall 
thickness and does not in itself require further evaluation. However, the additional presence of 
TWI, ST segment depression, or pathological Q waves should raise the possibility of 
pathological LVH and should prompt further evaluation. 
 
Right Ventricular Hypertrophy 
Voltage criterion for RVH is also fairly common in athletes with up to 13% of athletes fulfilling 
the Sokolow-Lyon index (R wave in V1 + largest S wave in V5 or V6 > 10.5 mV).21, 33 The 
presence of QRS voltage criterion for RVH correlates poorly with increased RV wall thickness 
on echocardiography.21 Most importantly, QRS voltages for RVH, when present in isolation, do 
not correlate with underlying pathology in athletes, in particular arrhythmogenic right ventricular 
cardiomyopathy (ARVC) or pulmonary hypertension.21 In a study comparing 627 athletes to 
patients with established ARVC or pulmonary hypertension, none of the athletes with isolated 
RVH by voltage criterion had any RV pathology on advanced cardiac imaging, and none of the 
patients with ARVC or pulmonary hypertension exhibited voltage criterion for RVH without 
additional ECG abnormalities.21 Based on these considerations, it is reasonable to conclude that, 
similar to voltage criteria for LVH, isolated QRS voltage for RVH is part of the normal spectrum 
of ECG findings in athletes and in the absence of other ECG or clinical markers of pathology 
does not require further evaluation. 
  
Incomplete Right Bundle Branch Block 
 
Incomplete RBBB is defined by a QRS duration < 120 ms with a RBBB pattern: terminal R 
wave in lead V1 (commonly characterized as an rSR’ pattern) and wide terminal S wave in leads 
I and V6 (Figure 4). Studies suggest that the mildly delayed RV conduction in athletes is caused 
by RV remodeling, with increased cavity size and resultant increased conduction time, rather 
than an intrinsic delay within the His-Purkinje system.42 Therefore, incomplete RBBB represents 
a phenotype of cardiac adaptation to exercise and in the absence of other features suggestive of 
disease does not require further evaluation.  
 
Early Repolarization 
 
By convention, early repolarization is defined as elevation of the QRS-ST junction (J-point) by ≥ 
0.1 mV often associated with a late QRS slurring or notching (J wave) affecting the inferior 
and/or lateral leads (Figure 2).43-45 Early repolarization is a common finding in healthy 
populations (2-44%) and is more prevalent in athletes, young individuals, males, and black 
ethnicity.43, 46-50 Early repolarization consisting of J-point elevation with concave ST segment 
elevation and a peaked T wave is present in up to 45% of Caucasian athletes and 63-91% of 
black athletes of African-Caribbean descent (hereto referred to as “black” athletes).32, 33  
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Some studies on survivors of cardiac arrest and patients with primary ventricular fibrillation 
(VF) have suggested an association between early repolarization and the risk of VF.44, 51 A study 
of middle-aged individuals demonstrated the presence of an early repolarization pattern in the 
inferior leads accompanied by a horizontal or descending ST segment after the J-point, was 
associated with an increased risk of arrhythmic death, while a rapidly ascending ST segment, the 
dominant ST pattern in healthy athletes, was associated with a benign prognosis.43, 46 Early 
repolarization of some subtypes appears to be a dynamic process in athletes which is affected 
directly by exercise training, increasing in frequency at times of peak fitness.48, 49, 52 Although 
further studies are warranted to fully elucidate the mechanisms and prognostic implications of 
early repolarization in competitive athletes, to date there are no data to support an association 
between inferior early repolarization and SCD in athletes. Based on current evidence, all patterns 
of early repolarization, when present in isolation and without clinical markers of pathology, 
should be considered benign variants in athletes.53  
 
Repolarization Findings in Black Athletes  
 
The electrocardiographic expression of the athlete’s heart is influenced by several factors. Over 
the past decade, ethnicity has emerged as a major determinant of cardiac adaptation to exercise 
with black athletes exhibiting a higher prevalence of electrocardiographic anomalies, including 
repolarization changes. Notably, more than two-thirds of black athletes exhibit ST segment 
elevation and up to 25% demonstrate TWI on their ECG.23, 33, 54, 55  
 
Black athletes also commonly demonstrate a repolarization variant consisting of J-point 
elevation and convex ST segment elevation in the anterior leads (V1-V4) followed by TWI 
(Figure 5). A study of 904 black male athletes of African descent demonstrated that 13% 
exhibited isolated TWI in leads V1-V4 compared to only 4% of black sedentary controls.33 The 
majority of anterior TWI were preceded by J-point elevation and convex (domed) ST segment 
elevation. None of the athletes with anterior TWI showed symptoms or signs of cardiomyopathy 
despite comprehensive evaluation and a 5-year follow-up period.33 Similar findings have been 
described in female and adolescent black athletes.54-56 Based on these considerations, TWI in 
leads V1-V4 when preceded by J-point elevation and convex ST segment elevation should be 
considered part of the “black athlete’s heart” and should not result in further investigation, in the 
absence of other clinical or ECG features of cardiomyopathy.  
 
Considerations in Athletes Age 12-16 Years: the “Juvenile” ECG Pattern 
 
TWI confined to the anterior precordial leads may be considered a normal age related pattern in 
adolescent athletes up to the age of 16 years old. The term “juvenile” ECG pattern is used to 
denote TWI or a biphasic T wave beyond lead V2 in adolescents who have not reached physical 
maturity (Figure 6). The juvenile pattern is present in 10-15% of white, adolescent athletes aged 
12 years old but only in 2.5% of white athletes aged 14-15 years.32, 57, 58 Anterior TWI that 
extends beyond lead V2 is rare (0.1%) in white athletes aged ≥ 16 years or younger athletes who 
have completed puberty when formal assessment by a pediatrician is feasible.32, 57 Based on 
current evidence, TWI in the anterior leads (V1-V3) in adolescent athletes < 16 years of age (or 
pre-pubertal athletes) should not prompt further evaluation in the absence of symptoms, signs or 
a family history of cardiac disease. 
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Sinus Bradycardia 
 
Sinus bradycardia is defined as a heart rate < 60 beats per minute (bpm) and is present in up to 
80% of highly trained athletes.32, 35 In normal sinus rhythm, the heart rate is determined by the 
balance between the sympathetic and parasympathetic nervous systems. Resting sinus 
bradycardia is particularly prevalent in endurance athletes due to increased vagal tone and 
possible structural atrial remodelling.59, 60 In the absence of symptoms such as fatigue, dizziness, 
or syncope, heart rates ≥ 30 bpm are considered normal in highly trained athletes. Sinus 
bradycardia should resolve with the onset of physical activity.  
 
Sinus Arrhythmia 
 
Sinus arrhythmia, the physiological fluctuation in heart rate with breathing, is considered a 
normal finding and should not be confused with sinus node dysfunction or sick sinus syndrome. 
Differentiating features that suggest sinus node dysfunction include lack of rhythmic changes in 
the heart rate, abrupt sustained rate increases and decreases, prolonged pauses or periods of sinus 
arrest, inappropriate rate response to exercise (including slowed acceleration and an 
inappropriately rapid deceleration), as well as any association with clinical symptoms such as 
exercise intolerance, pre-syncope and syncope. In sinus arrhythmia, the P wave axis remains 
normal in the frontal plane and the fluctuation in heart rate should resolve with the onset of 
exercise.   
 
Junctional Escape Rhythm 
 
A junctional escape (nodal) rhythm occurs when the QRS rate is faster than the resting P wave or 
sinus rate, which is typically slower in athletes due to increased vagal tone (Figure 7). The R-R 
interval is regular in a junctional escape rhythm, and the QRS complexes are narrow unless the 
baseline QRS has a bundle branch block. Sinus rhythm should resume with the onset of physical 
activity.  
 
Ectopic Atrial Rhythm 
 
In an ectopic atrial rhythm, P waves are present but of different morphology compared to the 
sinus P wave, typically with a rate ≤ 100 bpm. Ectopic P waves are most easily seen when the P 
waves are negative in the inferior leads (Figure 8). Occasionally, two different P wave 
morphologies may be seen and this is known as a ‘wandering atrial pacemaker’. A junctional 
escape rhythm or wandering atrial pacemaker is observed in up to 8% of all athletes under 
resting conditions.32 Ectopic atrial rhythms occur due to a slowed resting sinus rate from 
increased vagal tone in athletes. Sinus rhythm should resume with the onset of physical activity.   
 
First Degree AV Block 
 
First degree AV block is found in up to 7.5% of athletes on a resting ECG and is characterized 
by a prolonged (> 200 ms) PR interval.32, 35, 61 This represents a delay in AV nodal conduction in 
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athletes, due to increased vagal activity or intrinsic AV node changes, and typically resolves with 
the onset of exercise.    
 
Mobitz Type I (Wenckebach) Second Degree AV Block 
 
In Mobitz Type I second degree AV block, the PR interval progressively lengthens from beat to 
beat, until there is a non-conducted P wave with no QRS complex (Figure 9). The first PR 
interval after the dropped beat is shorter than the last conducted PR interval before the dropped 
beat. This represents a greater disturbance of AV nodal conduction than first degree AV block, 
but is usually a normal finding in asymptomatic, well-trained athletes, and 1:1 conduction should 
return with the onset of exercise. 
 
Sports-specific ECG Considerations 
 
Adaptive changes in cardiac structure, function and electrophysiology occur in response to 
regular intense physical training. A relatively strong relationship exists between the amount of 
training performed, resulting fitness, and extent of adaptive cardiac remodeling. Using measured 
VO2 max as a marker of athlete fitness, a robust linear association has been demonstrated 
between fitness and cardiac size.62 In this context, it is not surprising that many ECG features 
associated with athletic training are more prevalent and more profound in athletes exposed to the 
greatest training stimulus. This concept has most frequently been addressed by comparing 
athletes involved in team, skill-based or strength sports with those competing in endurance 
exercise. In a study comparing the ECGs of 1,010 elite non-endurance and 251 endurance 
athletes, the latter group demonstrated more frequent bradycardia, voltage criterion for LVH, and 
early repolarization – all features considered common, benign and training-related.63 However, 
uncommon features such as TWI extending to lead V3 was more common (4.0 vs. 1.1%, 
p<0.0001) in endurance athletes as compared with non-endurance athletes.63 Another study also 
reported a higher prevalence of TWI in the anterior septal leads in elite rowers compared to non-
endurance or mixed athletic cohorts.64 Incomplete and complete RBBB are also commonly 
observed in athletes with a prevalence which appears to increase with cardiac size, thereby 
suggesting it is more frequently observed in endurance athletes.42  
 
 
BORDERLINE ECG FINDINGS IN ATHLETES 
 
Overview of Borderline ECG Findings in Athletes 
 
Recent data suggests that some ECG findings previously categorized as abnormal may also  
represent normal variants or the result of physiological cardiac remodeling in athletes and do not 
usually represent pathological cardiac disease. These ECG findings, specifically axis deviation, 
voltage criteria for atrial enlargement, and complete RBBB, have been categorized as 
‘borderline’ findings in athletes (Figure 1; Table 1).  
 
Axis Deviation and Voltage Criteria for Atrial Enlargement 
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Several studies have shown that the Seattle criteria reduces the number of positive ECGs 
compared to the 2010 ESC criteria by at least 40% and improves specificity without 
compromising sensitivity.18, 23, 24, 65 Despite the improvements, more recent publications suggest 
that axis deviation and voltage criteria for atrial enlargement account for a large number of  ECG 
patterns that are classified as abnormal in athletes but do not correlate with cardiac pathology. In 
a large study of 2,533 athletes aged 14-35 years old and 9,997 controls of similar age, isolated 
left or right axis deviation and isolated left or right atrial enlargement comprised 42.6% of all 
ECG findings.22 The athletes revealed a slightly higher prevalence of these findings compared to 
controls (5.5% versus 4.4%; p=0.023). Specifically, athletes showed a higher prevalence of left 
axis deviation (LAD) and left atrial enlargement (LAE) versus controls (1.46% vs. 0.96%; 
p=0.028 and 2.13% vs. 1.37%; p=0.007, respectively), particularly in those who trained over 20 
hours per week.22 Whereas there were no significant differences in the prevalence of right axis 
deviation (RAD) and right atrial enlargement (RAE) between the groups (1.11% vs. 1.10%; 
p=0.983 and 0.83% vs. 0.92%; p=0.664, respectively).22 
 
Athletes with LAD or LAE exhibited larger left atrial and ventricular dimensions compared with 
athletes with a normal ECG and those with other physiological ECG changes consistent with 
athlete’s heart.22 However, there were no appreciable differences in the number of athletes with 
cardiac dimensions exceeding predicted upper limits between the two groups. In contrast, there 
were no differences in cardiac dimensions between athletes with RAD or RAE compared to 
athletes with normal or usual physiological ECG changes.22 Echocardiographic evaluation of the 
579 athletes and controls with isolated axis deviation or voltage criteria for atrial enlargement 
failed to identify any major structural or functional abnormalities, and the prevalence of minor 
congenital abnormalities was similar in these individuals to those with normal ECGs.22  
 
Exclusion of axis deviation or atrial enlargement reduced the false positive rate from 13% to 
7.5% and improved specificity from 90% to 94% with a minimal reduction in sensitivity (91% to 
89.5%).22 A U.S. study of 508 university athletes also revealed that of the 49 athletes considered 
to have abnormal ECGs at least 29 (59%) exhibited either voltage criteria for LAE alone or in 
combination with large QRS complexes, and subsequent echocardiography revealed a 
structurally normal heart or findings consistent with athletic training.39  
 
These findings suggest that RAD and RAE occurring in isolation or in association with other 
electrical markers of ‘athlete’s heart’ are probably normal variants, whereas LAD and LAE may 
reflect a relative increase in LV dimensions in some athletes. 
 
Complete Right Bundle Branch Block 
 
Although incomplete RBBB is common in young athletes, the significance of complete RBBB is 
less certain. This particular ECG pattern was placed in the abnormal category in the 2010 ESC 
recommendations and more recent ‘refined’ criteria, although considered a normal finding in the 
Seattle criteria if the QRS duration was < 140 ms.5, 10, 23 Complete RBBB is detected in 
approximately 1% of the general population and large datasets in young adult athletes reveal a 
prevalence of 0.5-2.5%.12, 66-68 In a study of 510 U.S. collegiate athletes, RBBB was reported in 
13 (2.5%) athletes and compared to athletes with normal QRS complexes and athletes with 
incomplete RBBB.42 The athletes with complete RBBB exhibited larger right ventricular 
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dimensions and a lower right ventricular ejection fraction but preserved fractional area change. 
None of the athletes with complete RBBB or incomplete RBBB was found to have pathological 
structural cardiac disease suggesting that that this particular ECG pattern may be a manifestation 
of more extreme right ventricular adaptation to exercise. These patterns among trained athletes 
could represent a spectrum of structural and physiological cardiac remodeling characterized by 
RV dilation with resultant QRS prolongation and a relative reduction in the RV systolic function 
at rest.42 
 
Based on the aforementioned considerations, LAD, LAE, RAD, RAE and complete RBBB are 
considered borderline variants in athletes. The presence of any one of these findings in isolation 
or with other recognized physiological electrical patterns of athletic training does not warrant 
further assessment in asymptomatic athletes without a family history of premature cardiac 
disease or SCD. Conversely, the presence of more than one of these borderline findings in 
combination places the athlete in the abnormal category warranting additional investigation 
(Figure 10). 
 
 
ABNORMAL ECG FINDINGS IN ATHLETES 
 
Overview of ECG Criteria for the Detection of Pathological Cardiac Disorders in Athletes 
 
Many pathological cardiac disorders associated with SCD exhibit abnormalities on a resting 
ECG. TWI is the most consistent electrical abnormality in patients with cardiomyopathy. ST 
segment depression, pathological Q waves, and left bundle branch block (LBBB) are also 
recognized in cardiomyopathic disorders and ischaemic heart disease. Primary electrical disease 
such as ventricular pre-excitation, LQTS, and BrS are suggested and/or diagnosed by abnormal 
ECG findings. None of these abnormal findings as defined in this section are recognized features 
of athletic training and always require further assessment to exclude the presence of intrinsic 
cardiac disease (Figure 1; Table 1; Table 2). When ECG abnormalities are identified, an athlete’s 
personal and family history should be thoroughly questioned as part of a comprehensive clinical 
investigation. 
 
Abnormal T Wave Inversion 
 
T waves represent repolarization or recovery of the ventricular myocardium and constitute the 
final waveform of the cardiac cycle on ECG. T waves can be described by numerous attributes 
including duration, symmetry, skewness, slope of the ascending and descending waveform, and 
most importantly, directionality. Directionality (i.e. positivity or negativity) refers to the 
direction of T wave deflection with regards to the electrically neutral ECG baseline, 
conventionally defined as the PR segment. T wave directionality is typically concomitant with 
the net vector of the QRS complex and is thus deflected above the baseline (i.e. positive) in most 
leads. Normal exceptions, leads in which T waves are routinely negative, include aVR, III, and 
V1. T waves deflected negatively are referred to as TWI. When present in leads aside from aVR, 
III, and V1, TWI may have an association with underlying structural heart disease. TWI ≥ 1 mm 
in depth in two or more contiguous leads (excluding leads aVR, III, and V1) in an anterior, 
lateral, inferolateral, or inferior territory is abnormal (with the exception of TWI confined to 
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leads V1-V4 in black athletes and leads V1-V3 in all athletes aged < 16 years) and should 
prompt further evaluation for underlying structural heart disease (Table 1; Table 2). 
 
Clinical Considerations 
The relationship between abnormal TWI and several forms of structural heart disease including 
HCM, ARVC, dilated cardiomyopathy (DCM), left ventricular non-compaction, and myocarditis 
is well documented. In a cohort of young (age < 35 years) asymptomatic patients with confirmed 
HCM, 62% exhibited abnormal TWI.69 In a similar study of asymptomatic or mildly 
symptomatic HCM patients, the prevalence of abnormal TWI was reported at 80%.70 Most 
recently, the prevalence of abnormal TWI among athletes with newly diagnosed HCM was 
reported in excess of 90%.71 In a study comparing 1,124 athletes with 255 patients with HCM, 
TWI in V4-V6 were present in 38% of patients with HCM versus 0.8% of athletes (p<0.001) 
(Figure 3).72  
 
ARVC is similarly associated with abnormal TWI. Specifically, the presence of TWI in the right 
precordial leads (V1-V3) or beyond in the absence of a complete RBBB is common among 
ARVC patients and has been adopted as a major criterion for diagnosis (Figure 11).73, 74 
Recently, the deleterious prognostic implications of TWI involving non-anterior lead territories 
among patients with ARVC, particularly inferior lead TWI, have been demonstrated.75, 76  
 
Abnormal TWI is relatively infrequent among healthy white competitive athletes with a reported 
prevalence ranging from < 1.0 to 4% based on factors including age, gender and type of sport but 
is reported in as many as 12% of black athletes.18, 32, 33, 39, 56, 64, 77-79 Based on the overlap with the 
cardiomyopathies, abnormal TWI in asymptomatic athletes warrants a comprehensive clinical 
assessment to exclude underlying cardiomyopathy. There are no data relating to the significance 
of flat or biphasic T waves in athletes. Similar to TWI, this panel would recommend further 
evaluation of biphasic T waves where the negative portion is ≥ 1 mm in depth in ≥ 2 leads. 
 
Evaluation 
Lateral or Inferolateral TWI 
There is mounting evidence that TWI in the lateral or inferolateral leads, in any athlete, are 
associated with the presence of quiescent cardiomyopathy.33, 79-81 Recommendations for the 
evaluation of abnormal TWI and other clinical considerations are presented in Table 2. 
 
Although rarely seen in athletes without subsequently identified structural heart disease, TWI 
affecting the lateral leads (V5-V6, I and aVL) is considered abnormal and should prompt 
comprehensive investigation irrespective of ethnicity, including cardiac MRI, when 
echocardiography is non-diagnostic. Echocardiographic quality is variable and may have limited 
ability to detect hypertrophy of the anterolateral LV wall and apex.82 Contrast-enhanced cardiac 
MRI provides superior assessment of myocardial hypertrophy and may demonstrate late 
gadolinium enhancement (LGE) which is a non-specific marker suggesting myocardial fibrosis. 
Exercise ECG testing and Holter monitoring also should be considered in the evaluation of 
lateral or inferolateral TWI, especially for ‘grey zone’ hypertrophy (maximal LV wall thickness 
13-16 mm) without LGE, where the diagnosis of HCM remains uncertain. In such cases, the 
presence of ventricular tachycardia during exercise or Holter may support a pathological 
diagnosis and is useful in risk stratification.83  
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Cardiac MRI should be a standard component of the assessment for markedly abnormal ECGs 
suggestive of apical HCM, specifically ECGs with deep (> -0.2 mV) TWI and ST segment 
depression in the lateral or inferolateral leads in which echocardiography may not provide 
adequate assessment of the LV apex and inferior septum. If cardiac MRI is not available, 
echocardiography with contrast should be considered as an alternative investigation for apical 
HCM. For athletes with lateral TWI, regular follow-up with serial cardiac imaging is necessary 
even when the initial evaluation is normal, in order to monitor for the development of a 
cardiomyopathy phenotype (Figure 12).80, 81 
 
Anterior TWI 
Anterior TWI is a normal variant in asymptomatic adolescent athletes age < 16 years and in 
black athletes when preceded by J-point elevation and convex ST segment elevation.84 Anterior 
TWI involving lead V3 is also reported in white, adult, predominantly endurance athletes.63 
However, anterior TWI in leads V1-V2/V3 also is a recognized pattern in patients with ARVC 
and more rarely HCM (Figure 11). There are discrepancies among existing guidelines relating to 
the extent of anterior TWI inversion before considering further investigations.5, 6, 16, 23  
 
A large study of over 14,000 white adults aged 16-35 years old, including over 2,500 athletes 
showed that anterior TWI had a prevalence of 2.3%.85 Anterior TWI was more common in 
females and athletes and was confined to leads V1-V2 in almost all individuals, and only 
exceeded beyond V2 in 1% of females and 0.2% of males.85 None of the individuals with 
anterior TWI were diagnosed with a cardiomyopathy following comprehensive investigation 
indicating that this particular ECG pattern is non-specific in low risk populations. Based on this 
report, it would be justifiable to investigate only athletes with anterior TWI beyond V2 in the 
absence of other clinical or electrical features of ARVC.  
 
Specific information about the J-point and preceding ST segment may help differentiate between 
physiological adaptation and cardiomyopathy in athletes with anterior TWI affecting leads V3 
and/or V4. A recent study comparing anterior TWI in a series of black and white healthy 
athletes, patients with HCM, and patients with ARVC, showed that in athletes with anterior TWI, 
the combination of J-point elevation ≥ 1 mm and TWI confined to leads V1-V4 excluded either 
cardiomyopathy with 100% negative predictive value, regardless of ethnicity.84 Conversely, 
anterior TWI associated with minimal or absent J-point elevation (< 1 mm) could reflect a 
cardiomyopathy.84 These data require duplication in larger studies but may prove useful in the 
assessment of a small proportion of white endurance athletes who exhibit anterior TWI and in 
athletes of black/mixed ethnicity.34   
 
In most non-black athletes age ≥ 16 years, anterior TWI beyond lead V2 should prompt further 
evaluation given the potential overlap with ARVC. The extent of evaluation is dependent on the 
specific ECG findings suggestive of ARVC and will be more extensive in the presence of 
warning symptoms or significant family history. In athletes age ≥ 16 years with TWI beyond V2, 
concurrent findings of J-point elevation, ST segment elevation, or biphasic T waves more likely 
represents athlete’s heart, while the absence of J-point elevation or a coexistent depressed ST 
segment is more concerning for ARVC.84 Other ECG findings suggestive of ARVC in the 
presence of anterior TWI include low limb lead voltages, prolonged S wave upstroke, ventricular 
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ectopy with LBBB morphology, and epsilon waves.74 A combination of tests is needed to 
effectively make the diagnosis of ARVC and may include echocardiography, cardiac MRI, 
Holter monitoring, exercise ECG test, and signal averaged ECG (SAECG).  
 
Repolarization variants in the anterior precordial leads in black athletes must be distinguished 
from pathological repolarization changes found in ARVC (Figure 13). In ARVC, the J-point 
and/or ST segment is usually isoelectric or depressed prior to TWI, in contrast to the J-point 
elevation and ‘domed’ ST segment elevation which is the hallmark feature of the physiological 
repolarization variant in black athletes.  
 
Inferior TWI 
The significance of TWI confined to the inferior leads (II, III, and aVF) has not been studied in 
detail. TWI isolated only to the inferior leads is not a strong predictor of cardiomyopathy in the 
absence of other abnormal ECG or clinical features. However, this finding cannot be attributed to 
physiological remodeling and thus warrants further investigation with, at minimum, an 
echocardiogram until larger studies with longer follow up prove otherwise. Cardiac MRI should 
be considered based on the echocardiographic findings or clinical suspicion. Serial assessment, 
on an annual basis, is advised until data from longitudinal studies become available.  
 
ST Segment Depression 
 
While ST segment depression is common among patients with cardiomyopathy, it is not a feature 
of athletic training (Figure 3). Prevalence estimates of ST segment depression among patients 
with HCM range from 60-70%, and in one study the territorial distribution of ST segment 
depression among HCM patients was associated with the risk of sudden death or appropriate 
implantable cardioverter-defibrillator therapy.41, 86, 87 In contrast, ST segment depressions are 
extremely rare in young athletes with structurally normal and physiologically remodeled 
hearts.33, 55, 68, 72 ST segment depression (relative to the isoelectric PR segment) in excess of 0.05 
mV (0.5 mm) in two or more leads should be considered an abnormal finding requiring definitive 
evaluation for underlying structural heart disease. 
 
Evaluation 
Echocardiography is the minimum evaluation for athletes with ST segment depression to 
investigate for underlying cardiomyopathy. Cardiac MRI should be considered based on the 
echocardiographic findings or clinical suspicion. 
 
Pathological Q Waves 
 
Q waves are defined as any initial negative deflection of the QRS complex and can be found 
with both physiological electrical activation of the ventricle and with certain pathological 
conditions, including cardiomyopathy, myocardial infarction, and conduction abnormalities.  
 
Several pathological disorders can lead to the development of exaggerated (deep or wide) Q 
waves or unexpected Q waves in atypical leads. HCM commonly results in asymmetric septal 
hypertrophy, which can produce abnormal Q waves due to increased septal forces, septal 
fibrosis, and asymmetric electrical activation (Figure 14). Indeed, pathological Q waves are 
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among the most common abnormal ECG findings in HCM and present in 32-42% of patients.41, 
69 Pathological Q waves can also result from prior transmural myocardial infarction. Any loss of 
myocardium and/or loss of myocardial electrical activity due to infarction, infiltration or fibrosis 
may lead to unopposed electrical activation of the opposite segments. Additionally, early 
activation from a bypass tract such as in WPW distorts the location of initial ventricular 
activation and may result in broad or atypical Q waves.  
 
Pathological Q waves also may be a result of lead misplacement. In particular, a pseudo-septal 
infarct pattern with pathological Q waves in leads V1-V2 is commonly due to high lead 
placement relative to cardiac position. This finding is more common in women than men, and in 
one series 64% of subjects lost this QS pattern on repeat ECG.88 
 
A physiological increase in myocardial mass, such as LVH from athletic remodeling, also can 
result in increased Q wave voltage, and the change in cardiac geometry and electrical axis may 
distort the location of Q waves slightly. Thus, although Q waves can be a marker of underlying 
heart conditions, differentiating physiological from pathological Q waves can be challenging.  
 
Pathological Q waves have been reported in approximately 1-2% of all athletes, and may be 
higher in males and black athletes.23, 89 For asymptomatic athletes, pathological Q waves were 
previously defined as > 3 mm in depth or > 40 ms in duration in two or more leads (except III 
and aVR).6, 10 In practice, however, this criterion is a common source of false positive ECG 
results as trained athletes with physiological LVH and thin adolescent athletes may have 
increased precordial voltages and deep lateral or inferior Q waves. Long narrow Q waves (> 3 
mm in depth) as previously defined by the Seattle criteria have been shown to be an unreliable 
marker for pathological LVH in athletes with increased QRS voltage. In a report of 13,335 
adolescents age 14-18 years screened with ECG, none of the 206 (1.5%) individuals with 
abnormal Q waves but no other ECG abnormality had pathological findings on limited 
echocardiogram consistent with cardiomyopathy.90 Thus, modification of the criteria for 
pathological Q waves has the potential to greatly improve the specificity of ECG interpretation. 
 
The use of a Q/R ratio overcomes some of these issues by normalizing Q wave depth to the 
degree of proceeding R wave voltage. Case control analyses of athletes and HCM patients 
suggest that this will decrease the false positive rate without compromising sensitivity for the 
detection of cardiomyopathy.23, 24 Therefore, the consensus of this panel based on existing 
scientific data is to modify the definition for pathological Q waves in athletes as a Q/R ratio ≥ 
0.25 or ≥ 40 ms in duration in two or more contiguous leads (except III and aVR). 
 
Evaluation 
 
An ECG with abnormal Q waves should be carefully examined for the possibility of a bypass 
tract, looking for a short PR interval or evidence of a delta wave. If the pathological Q waves are 
isolated to leads V1-V2, the ECG should be repeated, including re-placing the ECG leads to 
ensure proper positioning. Persistence of a QS pattern should undergo additional evaluation. 
 
Pathological Q waves in two or more contiguous leads warrants further investigation with 
echocardiography to exclude cardiomyopathy. A detailed family history and assessment of risk 
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factors for CAD also should occur, especially in athletes age ≥ 30 years as stress testing may be 
warranted in athletes with suspicion of prior myocardial infarction or multiple risk factors for 
CAD.   
 
If the echocardiogram is normal and there are no other concerning clinical findings or ECG 
abnormalities, no additional testing is generally necessary. If pathological Q waves are present 
along with other ECG abnormalities, such as ST segment depression or TWI, or if suspicious 
clinical findings are present, additional evaluation with cardiac MRI should be considered. 
 
Complete Left Bundle Branch Block 
 
LBBB is found in less than 1 in 1,000 athletes but is common in patients with cardiomyopathy 
and ischaemic heart disease.9, 41, 72, 91, 92 Thus, complete LBBB always should be considered an 
abnormal finding and requires a comprehensive evaluation to rule out a pathological cardiac 
disorder. 
 
LBBB is recognized by a QRS ≥ 120 ms, predominantly negative QRS complex in lead V1 (QS 
or rS), and upright notched or slurred R wave in leads I and V6 (Figure 15). Q waves are often 
absent in leads I, V5, and V6, and the ST segment and T waves are usually in the opposite 
direction than the QRS.93 
 
Evaluation 
Athletes with complete LBBB require a thorough investigation for myocardial disease including 
echocardiography and a cardiac MRI with perfusion study.  
 
Profound Nonspecific Intra-ventricular Conduction Delay 
 
Epidemiological studies of nonspecific intra-ventricular conduction delay (IVCD) in the general 
population have shown an increased risk of cardiovascular death and have been documented 
among patients with cardiomyopathy.94, 95 The significance of nonspecific IVCD with normal 
QRS morphology in healthy, asymptomatic athletes is uncertain.96 The physiology underlying 
IVCD in athletes remains incompletely understood but likely includes some combination of 
neurally mediated conduction fiber slowing and increased myocardial mass. In patients with 
LVH, left ventricular mass seems to be closely related to QRS duration.97 
 
While the exact cutoff to trigger more investigation in athletes with a nonspecific IVCD remains 
unclear, this panel recommends that marked nonspecific IVCD ≥ 140 ms in athletes, regardless 
of QRS morphology, is abnormal and should prompt further evaluation. In asymptomatic athletes 
with isolated nonspecific IVCD < 140 ms, no further diagnostic evaluation is required. Athletes 
with cardiovascular symptoms or a concerning family history of sudden death or suspected 
cardiomyopathy with a nonspecific IVCD ≥ 140 ms or in tandem with other ECG abnormalities 
should be evaluated further.  
  
Evaluation 
19 
 
In asymptomatic athletes with profound nonspecific IVCD, an echocardiogram is recommended 
to evaluate for myocardial disease. Other testing may be indicated depending on 
echocardiographic findings or clinical suspicion. 
 
Epsilon Waves 
 
Epsilon waves are defined as distinct low amplitude signals localized between the end of the 
QRS complex and onset of the T wave in leads V1-V3. Epsilon waves are challenging to detect 
and appear as a small positive deflection or notch just beyond the QRS in leads V1-V3. The 
presence of epsilon waves is a highly specific ECG marker and represents a major diagnostic 
criterion for ARVC.74 
 
Evaluation 
The evaluation of epsilon waves is focused on the diagnosis or exclusion of ARVC through a 
combination of tests including echocardiography, cardiac MRI, Holter monitoring, exercise ECG 
test, and signal averaged ECG. 
 
Ventricular Pre-Excitation 
 
Ventricular pre-excitation occurs when an accessory pathway bypasses the AV node resulting in 
abnormal conduction to the ventricle (pre-excitation) with shortening of the PR interval and 
widening of the QRS. This is evident on the ECG as the Wolf-Parkinson-White (WPW) pattern 
defined as a PR interval < 120 ms, the presence of a delta wave (slurring of the initial QRS), and 
a QRS duration > 120 ms (Figure 16).93 The WPW pattern occurs in approximately 1/1,000 to 
4/1,000 athletes.9, 12, 66, 98 The presence of an accessory pathway can predispose an athlete to 
sudden death because rapid conduction of atrial fibrillation across the accessory pathway can 
result in VF.  
 
Evaluation 
A short PR interval associated with a delta wave is consistent with the WPW pattern and 
warrants further assessment of the refractory period of the accessory pathway. A short PR 
interval in isolation without a widened QRS or delta wave in an asymptomatic athlete should not 
be considered for further assessment.  
 
Asymptomatic athletes with WPW pattern should be investigated for the presence of a low or 
high risk accessory pathway. Non-invasive risk stratification begins with an exercise stress test, 
where abrupt, complete loss of pre-excitation at higher heart rates suggests a low risk accessory 
pathway.99, 100 Intermittent pre-excitation during sinus rhythm on a resting ECG is also consistent 
with a low risk pathway and may obviate the need for an exercise test.101 If non-invasive testing 
cannot confirm a low risk pathway or is inconclusive, electrophysiology testing should be 
considered to determine the shortest pre-excited RR interval during atrial fibrillation.99 If the 
shortest pre-excited RR interval is ≤ 250 ms (240 bpm), then the accessory pathway is deemed 
high risk.99, 102 Young athletes with a shortest pre-excited RR interval ≤ 250 ms should proceed 
with transcatheter ablation.99 An echocardiogram also should be considered due to the 
association of WPW with Ebstein’s anomaly and cardiomyopathy. Some physicians may choose 
to subject all competitive athletes involved in moderate or high intensity sport to 
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electrophysiological studies irrespective of the results of the exercise test or 24 hour ECG on the 
premise that high catecholamine concentrations during very intensive exercise may modify the 
refractory period of an accessory pathway in a fashion that cannot be reproduced during 
laboratory tests.    
 
Prolonged QT Interval 
 
Congenital LQTS is a potentially lethal, genetically mediated ventricular arrhythmia syndrome 
with the hallmark electrocardiographic feature of QT prolongation. Symptoms if present include 
arrhythmic syncope, seizures, or aborted cardiac arrest/sudden death stemming from torsades de 
pointes and VF. The pathophysiology of LQTS involves delayed ventricular repolarization 
originating primarily from loss-of-function mutations in genes encoding voltage gated potassium 
channels that govern phase 3 repolarization. LQTS is estimated to affect 1 in 2,000 individuals, 
and this may be underestimated given the subpopulation of so-called “normal QT interval” or 
“concealed” LQTS.103 
 
Autopsy negative sudden unexplained death represents 25-40% of sudden unexpected deaths in 
persons under age 40 years.3, 104-106 In cases that lack necropsy findings to establish a cause of 
death, cardiac ion channelopathies have been implicated by post-mortem genetic testing as the 
probable cause in up to 25-35% of sudden unexplained death in selected cohorts.107-110  
 
Calculating the QTc 
Accurate measurement and manual confirmation of the computer derived QT interval corrected 
for heart rate (QTc) is critical as the accuracy of computer generated QTc values is about 90-
95%. Studies have suggested the ability of cardiologists and even heart rhythm specialists to 
accurately measure the QTc is suboptimal.111 However, accurate assessment of the QTc can be 
achieved by adhering to the following six principles:112  
 
1. Most ECG devices utilize the Bazett’s heart rate correction formula (QTc = QT/√RR; 
note the RR interval is measured in seconds).113 Although there are many heart rate 
correction formulas for the QTc, it is recommended to use Bazett’s correction to confirm 
the computer’s QTc as population-based QTc distributions most frequently have used 
Bazett-derived QTc values.  
2. Bazett’s formula loses accuracy at slow and fast heart rates; underestimating the inherent 
QTc at heart rates < 50 bpm, and overestimating the QTc at heart rates > 90 bpm. 
Accordingly, if an athlete has a heart rate < 50 bpm, a repeat ECG after mild aerobic 
activity is recommended to achieve a heart rate closer to 60 bpm where the formula is 
most accurate. Likewise, for heart rates > 90 bpm, repeating the ECG after additional 
resting time and ensuring the patient is not unduly cold, hot, or anxious may help achieve 
a lower heart rate where Bazett’s formula will be more accurate. 
3. If sinus arrhythmia is present with beat to beat variation in heart rate, an average QT 
interval and average RR interval should be used to improve accuracy. Importantly, taking 
the maximum QT interval and dividing it by the square root of the shortest RR interval on 
the ECG will grossly overestimate the QTc.114 
4. To properly perform a manual QT measurement, it is critical to identify the end of the T 
wave since the onset of the QRS is typically seen easily. Leads II and V5 usually provide 
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the best delineation of the T wave, and these leads are often used for the rhythm strip at 
the bottom of the ECG.   
5. Low amplitude U waves, common in the anterior precordial leads, should not be included 
in the QT calculation. Such U wave inclusion will greatly exaggerate the QTc. Instead, 
the “Teach-the-Tangent” or “Avoid-the-Tail” method to delineate the end of the T wave 
should be followed (Figure 17).112   
6. The morphology of the T wave, not just the length of the QT interval, also can suggest 
the presence of LQTS.115 For instance, a notched T wave in the lateral precordial leads 
where the amplitude of the second portion of the T wave following the notch is greater 
than the first portion of the T wave may represent LQT-2 even in the absence of overt QT 
prolongation. 
 
With this framework, the easiest and most efficient way to confirm the computer-derived QTc is 
to examine lead II and/or V5 and determine if the manually measured QT interval matches the 
computer’s QT measurement. If there is concordance within about 10 ms of each other, one can 
trust that the computer can derive accurately an average RR interval and complete the Bazett’s 
calculation. If, however, the manually measured QT interval is > 10 ms different than the 
computer’s QT measurement, an average RR interval should be determined and the QTc 
recalculated using the Bazett’s formula.  
 
QTc Cutoffs 
Given the overlap between QTc distributions in population-derived cohorts of healthy 
individuals compared to patients with genetically confirmed LQTS, it must be acknowledged 
that no screening program will identify all persons with LQTS.116-119 Instead, the QTc cutoff 
value, where the QTc measurement compels further evaluation, must be chosen carefully to 
balance the frequency of abnormal results and the positive predictive value that LQTS has been 
detected incidentally.   
 
Published definitions of a “prolonged QTc” requiring further evaluation have varied. Prior 
guidelines from the ESC for ECG interpretation in athletes define a QTc of > 440 ms in males 
and > 460 ms in females (but < 500 ms) as a ‘grey zone’ requiring further evaluation, and a QTc 
≥ 500 ms, otherwise unexplained and regardless of family history and symptoms, as indicative of 
unequivocal LQTS.5 In the U.S., the AHA/ACC/HRS guideline has dropped the term 
“borderline” QT prolongation and instead annotates a QTc > 450 ms in men and > 460 ms in 
women as “prolonged QTc”.120 Concern has been raised that these QTc cutoffs will produce a 
high number of false-positive test results if followed in a screening population of athletes.116 
More recent consensus statements on ECG interpretation in athletes have recommended that 
male athletes with a QTc > 470 ms and female athletes with a QTc > 480 ms undergo further 
evaluation for LQTS to better balance false-positive and false-negative findings.6, 10 These cutoff 
values are around the 99th percentile and consistent with thresholds defined by the 36th Bethesda 
Conference.121 This consensus group also recommends QTc values of > 470 ms in males and > 
480 ms in females to define the threshold of QT prolongation that warrants further assessment in 
asymptomatic athletes.  
 
Short QT Interval 
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While an abnormal cutoff for a short QT interval has been included in past ECG interpretation 
guidelines, the precise cutoff and clinical significance of a short QT interval in athletes is 
unknown. Data from over 18,000 asymptomatic young British individuals suggests that the 
prevalence of a QTc < 320 ms is 0.1%; suggesting an abnormal cutoff value of < 320 ms is 
pragmatic.122 However, over a mean follow up period of 5.3 years, none of the individuals with a 
short QT < 320 ms experienced any adverse events, syncope, or sudden death.122 Based on the 
rarity of this finding and absence of data to suggest long-term morbidity in asymptomatic 
athletes, the consensus of this panel recommends that a short QT interval only be investigated in 
the context of concerning clinical markers such as syncope, premature atrial fibrillation, 
ventricular arrhythmias, or a relevant family history. 
 
Evaluation 
An athlete identified with a prolonged QTc (≥ 470 ms in males; ≥ 480 ms in females) should 
undergo further evaluation. It is critical that an athlete with a single QTc reading above these 
threshold values not be obligated a diagnosis of LQTS, but rather that these cutoff values have 
triggered the need for additional evaluation. The importance of additional evaluation but not a 
premature diagnosis of LQTS was demonstrated in a study of 2,000 elite athletes in which 7 
(0.4%) had a prolonged QTc (range 460-570 ms).123 A QTc of < 500 ms in the absence of 
symptoms or familial disease was unlikely to represent LQTS. In contrast, a QTc ≥ 500 ms was 
highly suggestive of LQTS as all three athletes with a QTc value of > 500 ms exhibited one of 
paradoxical prolongation of the QTc during exercise, a confirmatory genetic mutation, or 
prolonged QTc in a first-degree relative.123 As outlined below, personal symptoms, family 
history, scoring systems, electrocardiographic features, stress ECG and genetic testing may be 
needed to clarify the diagnosis.   
 
A personal history of exercise/emotion/auditory-triggered syncope or seizures and a family 
history of exertional syncope, exercise/auditory-triggered “epilepsy”, postpartum-timed 
syncope/seizure, unexplained motor vehicle accidents, unexplained drowning, and premature, 
unexplained sudden death < 50 years of age should be reviewed. If the personal/family history is 
positive, the athlete should be referred to a heart rhythm specialist for further evaluation. If the 
personal/family history is negative, a repeat ECG should be obtained (ideally on a different day). 
If the follow-up ECG is below the QTc cutoff values, then no additional evaluation is needed and 
the athlete should be reassured.   
 
On the other hand, if the repeat ECG still exceeds the QTc cutoff values, then a screening ECG 
of the athlete’s first degree relatives (parents and siblings) should be considered and the athlete 
should be referred to a heart rhythm specialist or cardiologist for the possibility of newly 
discovered LQTS. Reversible, extrinsic factors, such as electrolyte abnormalities (hypokalemia) 
or the presence of QT prolonging medications, must also be evaluated. If an athlete’s ECG 
shows a QTc > 500 ms and no reversible causes are identified, then the athlete should be referred 
immediately to a heart rhythm specialist or cardiologist as the probability of LQTS and future 
adverse events has increased.124 Further testing, such as provocative treadmill stress testing, 
epinephrine QT stress testing, and genetic testing need to be considered carefully and should be 
performed and interpreted by a cardiologist familiar with the disease.  
 
23 
 
LQTS is diagnosed based on a combination of symptoms, family history, electrocardiographic 
findings, and genetic testing, and the Schwartz-Moss score used to invoke low, intermediate, and 
high probability.125-127  Genetic testing for LQTS is recommended for any athlete where a 
cardiologist has an index of suspicion for LQTS (intermediate or high probability score), or for 
an asymptomatic patient with no family history but an incidental ECG finding with a QTc > 480 
ms pre-puberty and > 500 ms post-puberty that is confirmed on repeat ECG testing.128 
 
Brugada Type 1 Pattern 
 
Brugada syndrome (BrS) is a primary electrical disease characterized by the distinctive Brugada 
ECG pattern of “high take-off” ST segment elevation in the right precordial leads (Figure 6). 
Although three types were described, only the type 1 Brugada pattern is now considered 
diagnostic.129-131 BrS predisposes to ventricular tachyarrhythmias in the absence of clinically 
demonstrable structural heart disease, and sudden death in patients with BrS occurs more often 
during states of enhanced vagal tone.132 Loss of function mutations in the sodium channel gene 
SCN5A accounts for up to 20% of cases.129, 133 BrS is estimated to cause up to 4% of all sudden 
deaths in the general population and 5-20% of sudden unexplained deaths with a structurally 
normal heart at autopsy.129, 134 
 
The type 1 Brugada pattern consists of a coved rSr’ pattern, ST-segment elevation ≥ 2 mm, and 
inversion of the terminal portion of the T wave in leads V1, V2, and V3. Classic type 2 and 3 
Brugada patterns have a “saddleback” appearance with J-point elevation ≥ 2 mm, ST segment 
elevation > 1 mm in type 2 and ≤ 1 mm in type 3, and either a positive or biphasic T wave. A 
recent consensus document grouped the classic types 2 and 3 as type 2.130  
 
Distinguishing between true type 1 or 2 patterns and a host of Brugada-like ECG patterns can be 
challenging. Brugada-like patterns may be caused by both physiological (normal variant, early 
repolarization, incomplete RBBB) and pathological (ARVC, pulmonary hypertension, 
hyperkalemia) conditions.130, 135 Pharmacologic and electrocardiographic maneuvers may clarify 
the diagnosis. Confirmation of proper precordial lead placement is paramount, as high placement 
of the V1 and V2 electrodes in the 2nd and 3rd intercostal space (rather than the 4th intercostal 
space) can accentuate a type 1 Brugada ECG pattern in known Brugada patients but also produce 
type 2 like patterns in athletes.136  
 
The coved ST segment elevation in type 1 Brugada pattern results in a broad r’ and should be 
distinguishable from the upsloping ST segment elevation of early repolarization in an athlete. In 
this regard, the “Corrado index” measures the ST elevation at the start of the ST segment/J-point 
(STJ) and 80 ms after the start of the ST segment (ST80).137 In type 1 Brugada pattern the 
downsloping ST segment will have a STJ/ST80 ratio > 1, while the initial upsloping of the ST 
segment found in early repolarization patterns in an athlete will produce an STJ/ST80 ratio < 1 
(Figure 18).  
 
Evaluation 
The type I Brugada ECG pattern is not a recognized variant of athlete’s heart and should raise 
the possibility of a sodium ion channelopathy. Patients with a type 1 ECG pattern should be 
referred to a cardiac electrophysiologist for further evaluation, regardless of symptoms. If the 
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pattern is unclear, confirm correct lead placement, repeat the ECG if necessary, and perform a 
high precordial lead ECG with V1 and V2 placed in the 2nd or 3rd intercostal space. If the type 1 
pattern is seen on high precordial lead ECG, then referral to a heart rhythm specialist is 
indicated. Consideration should be given to potential accentuating factors for a Brugada-like 
ECG pattern, such as hyperkalemia, fever, medications with sodium ion channel blocking 
properties, and lead placement.  
 
The type 2 Brugada ECG pattern may overlap with repolarization changes in the anterior leads in 
black athletes and endurance athletes. Multiple criteria for evaluating type 2 patterns have been 
proposed; however, in the absence of symptoms or a concerning family history, athletes with 
type 2 patterns do not require further testing. 
 
Profound Sinus Bradycardia 
 
Sinus bradycardia is a hallmark feature of athletic conditioning with heart rates commonly 
between 40-60 bpm or even slower. A resting heart rate ≤ 30 bpm or a sinus pause ≥ 3 seconds 
may be normal in a well-trained athlete but nevertheless should prompt further evaluation.  
 
Evaluation 
Evaluation of profound sinus bradycardia should include assessing the chronotropic response to 
mild aerobic activity, such as running on the spot or climbing stairs. If the heart rate increases 
appropriately and the athlete is asymptomatic, no further testing is necessary. If there is no 
change in heart rate or in athletes with a history of symptoms such as pre-syncope or syncope, 
further testing should be performed to exclude primary sinus node disease. Exercise testing is 
useful in this situation to provide an objective measure of the heart rate response to aerobic 
activity. 
 
Profound First Degree Heart Block 
 
Mild to moderate first degree heart block with a PR interval of 200 to 399 ms may be present in 
athletes due to increased vagal tone. A PR interval ≥ 400 ms is significantly prolonged and 
requires further evaluation.  
 
Evaluation 
A small amount of aerobic activity should be performed to assess if the PR interval shortens 
appropriately. If the PR interval normalizes with exercise, the PR prolongation is due to vagal 
mechanisms and is benign. If the PR interval does not shorten, or there are symptoms of syncope 
or a family history of cardiac disease or sudden death, further evaluation should be performed.138 
An exercise test can demonstrate more clearly if the PR interval changes at higher heart rates. 
Depending on the clinical scenario, an echocardiogram or ambulatory ECG monitor may be 
indicated.  
 
High Grade AV Block 
 
Mobitz type II second degree AV block and third degree (complete) AV block are pathological 
disruptions in AV conduction and abnormal findings in athletes. In Mobitz type II AV block, 
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there are intermittently non-conducted P waves with a fixed PR interval. In complete AV block, 
there are more P waves than QRS complexes, and the ventricular rhythm is regular due to an 
undisturbed junctional or ventricular pacemaker. Complete heart block can be confused with AV 
dissociation without block; a situation where the junctional pacemaker is faster than the sinus 
node, leading to more QRS complexes than P waves. Intermittent ventricular capture by sinus P 
waves (resulting in an irregular ventricular response) excludes complete AV block. AV 
dissociation without block is the expression of autonomic mismatch between AV and sinus nodal 
modulation, but is not pathological. Like all other functional disturbances, a small exercise load 
with repeat ECG recording will show resolution of the ECG findings in AV dissociation.  
Complete heart block requires further evaluation for underlying cardiac disease. 
 
Evaluation 
If Mobitz II AV block or complete AV block is detected, further evaluation includes an 
echocardiogram, ambulatory ECG monitor, and exercise ECG test. Based on these results, 
laboratory testing and cardiac MRI may be considered. Referral to a heart rhythm specialist is 
essential. 
 
Multiple Premature Ventricular Contractions 
 
Multiple (≥ 2) premature ventricular contractions (PVCs) are uncommon and present in < 1% of 
athlete ECGs (Figure 19).9, 12 When 2 or more PVCs are recorded on a standard (10 second) 
ECG, it is possible the athlete has a high 24 hour PVC burden. While multiple PVCs are most 
likely benign in a highly trained athlete, their presence may be the hallmark of underlying heart 
disease.139 In athletes with ≥ 2,000 PVCs per 24 hours, up to 30% were found to have underlying 
structural heart disease, in contrast to 3% and 0% in those with < 2,000 and < 100 PVCs per day, 
respectively.140 Over half of the athletes with ≥ 2,000 PVCs also had bursts of non-sustained 
ventricular tachycardia.140 Therefore, the finding of ≥ 2 PVCs on an ECG should prompt more 
extensive evaluation to exclude underlying structural heart disease.  
 
Evaluation  
The extent of evaluation for ≥ 2 PVCs is controversial and excluding pathology may be difficult. 
At a minimum, an ambulatory Holter monitor, echocardiogram, and exercise stress test should be 
performed. The availability of modern small, leadless ambulatory recorders allows for longer 
electrocardiographic monitoring, including during training and competition, to exclude complex 
ventricular arrhythmias. If the Holter and echocardiogram are normal and the PVCs suppress 
with exercise, no further evaluation is recommended for an asymptomatic athlete. However, in 
athletes with ≥ 2,000 PVCs per 24 hours or with episodes of non-sustained ventricular 
tachycardia, or with an increasing burden of ectopy during an incremental exercise test, 
additional evaluation may include contrast-enhanced cardiac MRI and more invasive EP 
study.141 Therefore, many such cases require referral to a specialist center.142 Although some 
studies have suggested that regression of the PVC burden with detraining indicates a good 
prognosis, other studies have not confirmed this.143-145 Thus, detraining as a diagnostic or 
therapeutic measure is not recommended. 
 
Considerations in High-Dynamic Athletes 
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In high-level endurance athletes, such as cyclists, triathlon athletes, and rowers, concern has been 
raised about the high volume and pressure loads on the right ventricle that could promote or 
induce ARVC. Competitive sport definitively accelerates and enhances the phenotypic 
expression of desmosomal mutations causing ARVC.146, 147 There also is evolving evidence that 
high-dynamic exercise sustained over a long period of time may result in ‘exercise-induced’ 
ARVC, even in the absence of desmosomal mutations or a familial history.142, 148-150 PVCs 
originating from the right ventricular outflow tract conduct with LBBB and an inferior axis and 
are usually regarded as benign when associated with an otherwise normal ECG; however, this 
PVC morphology can also be present in patients with early ARVC particularly when the QRS 
exceeds 160 msec.151 In contrast, PVCs originating from the main body of the right ventricle 
typically show a LBBB pattern and superior axis (predominantly negative QRS vector in V1 and 
the inferior leads) and may be associated with right ventricular pathology particularly in the 
context of other ECG abnormalities (Figure 19). Therefore, a lower threshold for extensive 
evaluation of a single PVC may be warranted in high-dynamic athletes, especially when ≥ 25 
years of age and with a LBBB morphology and superior axis. 
 
Atrial Tachyarrhythmias 
 
Atrial tachyarrhythmias, comprised of supraventricular tachycardia (SVT), atrial fibrillation, and 
atrial flutter, are heart rhythms > 100 bpm which originate in the sinus node, atrial tissue, or AV 
node. Sinus tachycardia is the most common atrial tachyarrhythmia but is very rarely due to 
intrinsic cardiac disease.  
 
SVT, atrial fibrillation, and atrial flutter are rarely seen on a resting ECG in athletes and require 
investigation. One study demonstrated just 6 of 32,561 young athletes during ECG screening 
with an atrial tachyarrhythmia, four (0.01%) with ectopic atrial tachycardia and two (<0.01%) 
with atrial fibrillation.9 An examination of ECGs from the South Korean Army also found zero 
soldiers with an atrial tachyarrhythmia.152 Atrial tachyarrhythmias are rarely life-threatening and 
usually lead to symptoms like palpitations, shortness of breath, chest pressure, dizziness, neck 
pounding, or syncope from rapid heart rates. AV dyssynchrony also may limit peak physical 
activity. More importantly, they can be associated with other conditions that can lead to SCD, 
including LQTS, WPW, BrS, myocarditis, congenital heart disease, and any form of 
cardiomyopathy.  
  
Evaluation  
For paroxysmal SVT, a repeat ECG when not in SVT should be obtained if possible. If the 
Valsalva maneuver, carotid sinus massage, or the diving reflex is used to terminate the 
arrhythmia, a rhythm strip should be obtained to assess whether the SVT terminates with a P 
wave or QRS complex, which can help elucidate the mechanism of the SVT. An 
echocardiogram, ambulatory ECG monitor, and exercise treadmill test should be completed, and 
referral to a heart rhythm specialist may be indicated for consideration of electrophysiology 
study and ablation.  
 
If atrial fibrillation or flutter is found, an echocardiogram should be completed to assess for 
structural heart disease and anti-coagulation considered based on standard guidelines.153 An 
ambulatory ECG monitor should be used to assess if the rhythm is paroxysmal or persistent and 
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what the ventricular rate is throughout the day. An exercise treadmill test also should be 
completed to assess the maximum heart rate in atrial fibrillation. A thorough family history may 
elucidate an underlying genetic cause. Depending on what these results show, cardiac MRI, 
electrophysiology study with possible ablation, and/or genetic testing may be considered.   
 
If resting sinus tachycardia > 120 bpm is seen, a repeat ECG should be considered after a period 
of rest as recent exercise or anxiety may be the cause. Other underlying etiologies may be 
sought, including fever, infection, dehydration, stimulant use, anemia, hyperthyroidism, or, 
rarely, underlying cardiac or pulmonary disease.  
 
Ventricular Arrhythmias 
 
Ventricular couplets, triplets, and non-sustained ventricular tachycardia always require 
investigation. Alone, these are not life-threatening arrhythmias, but can be a marker for 
underlying cardiac pathology or lead to sustained ventricular tachycardia which may cause SCD. 
These ventricular arrhythmias may be idiopathic or secondary to the cardiomyopathies, ion 
channelopathies, or other diseases such as myocarditis, myocardial infarction, or sarcoidosis.   
 
Evaluation 
If ventricular arrhythmias are seen, the evaluation should include a thorough family history, an 
echocardiogram to evaluate for structural heart disease, cardiac MRI to assess for ARVC or other 
cardiomyopathies, ambulatory ECG monitor and exercise ECG test. Depending on these results, 
further evaluation may be needed including electrophysiology study or genetic testing. 
 
Considerations in Athletes ≥ 30 Years of Age 
 
In athletes ≥ 30 years of age, CAD is the most common cause of SCD.105, 106 The number of 
older, masters athletes at all levels of competition is increasing worldwide. In addition, older 
athletes may be less fit compared to 20-30 years ago, increasing the possibility of underlying 
CAD.154 In a cohort study of Swedish competitive cross-country runners with a mean age of 60 
years, 2% were shown to have severe underlying cardiovascular disease, mainly CAD.155 While 
the overall health benefits of regular exercise and physical activity are unequivocal, exercise may 
be a trigger for acute cardiac events in individuals with underlying and silent CAD. The risk of 
an acute cardiovascular event during exercise seems to be U-shaped, with the greatest risk 
conferred in those who are physically inactive but also in those exercising at the highest 
intensity. Therefore, it is important to consider relevant changes on a resting ECG that may 
represent occult CAD in asymptomatic athletes ≥ 30 years of age.   
 
While resting ECGs have a low sensitivity for CAD, some ECG patterns may suggest underlying 
CAD such as TWI, pathological Q waves, ST segment depression, left or right bundle branch 
block, abnormal R wave progression, left anterior hemiblock, and atrial fibrillation.156-158 Thus, 
the major role of a resting ECG in screening for CAD may be in older athletes generally 
considered to be at an intermediate risk, where an abnormal ECG would place them into a high 
risk group warranting further testing.157, 159, 160 
 
Evaluation 
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Additional evaluation for underlying CAD should be considered in asymptomatic older athletes 
with TWI, pathological Q waves, ST segment depression, left or right bundle branch block, 
abnormal R wave progression, left anterior hemiblock, and atrial fibrillation. Initial testing 
should normally include an exercise stress test, resting echocardiogram, and assessment of 
traditional risk factors for CAD. When indicated, this evaluation may be complemented by 
coronary CT angiography or a functional stress test.  
 
ECG Patterns Requiring Serial Follow-up 
 
All abnormal ECG findings discussed in this document should prompt a comprehensive 
evaluation for underlying structural and/or electrical heart disease. The specific components of 
this evaluation should be individualized to the athlete based on the presence or absence of 
symptoms and relevant family history and on the specific attributes of the abnormal ECG. While 
the abnormal findings delineated in this document were chosen to maximize specificity for true 
underlying disease and therefore minimize the likelihood of false positive ECG testing, no single 
ECG abnormality has perfect accuracy. Further, ECG abnormalities may precede the 
development of overt structural heart disease in athletes with a genetic predisposition to 
cardiomyopathy.41, 80, 81 Athletes who demonstrate one or more overtly abnormal ECG findings 
may therefore undergo comprehensive clinical evaluations that reveal no definitive evidence of 
true pathology. In these cases, the clinical significance of the presenting abnormal ECG remains 
uncertain.  
 
Several common heritable cardiomyopathies including HCM, ARVC, and familial DCM may 
present with ECG abnormalities prior to the onset of overt heart muscle pathology. The natural 
history of athletes with markedly abnormal ECGs but structurally normal hearts on initial 
evaluation was first documented in a study of 81 athletes in which 6% (5/81) developed overt 
cardiomyopathy (HCM, n=3; ARVC, n=1; DCM, n=1) during an average follow-up period of 9 
years.80 In a more recent series of athletes with abnormal ECG findings, 6% (5/85) with initially 
unrevealing clinical evaluations developed features consistent with cardiomyopathy (HCM, n=2; 
ARVC, n=1; arrhythmic event, n=2) during a 12 month follow-up period.81    
  
Therefore, athletes with abnormal ECGs suggestive of cardiomyopathy and initially normal 
clinical evaluations should be followed with serial evaluation during and after their competitive 
athletic careers. Specifically, asymptomatic athletes with abnormal TWI, ST segment depression, 
pathological Q waves, LBBB, and profound IVCD (QRS duration ≥ 140 ms) require serial 
cardiac imaging to rule out the development of a cardiomyopathic disease (Figure 12). These 
athletes may be permitted to participate in competitive athletics without restriction contingent on 
longitudinal follow-up. Follow-up assessments should include a medical history to ascertain new 
cardiovascular symptoms or otherwise unexplained decrements in exercise tolerance, a physical 
examination, and non-invasive cardiac imaging as deemed suitable for the appropriate suspected 
form of disease. These evaluations should be conducted on an annual basis while participating in 
competitive athletics, or more frequently as determined on an individual basis. Athletes should 
be educated about the importance of longitudinal surveillance to promote ownership of the 
process if they change teams, medical staff, or locations.  
  
Temporary Restriction during Secondary Evaluation of ECG Abnormalities 
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Temporary restriction from athletic activity should be considered for athletes with abnormal 
ECGs of uncertain clinical significance until secondary investigations are completed. While the 
absolute risk of suffering an adverse cardiac event attributable to underlying structural or 
electrical heart disease is low while awaiting definitive evaluation, the risk is not negligible. 
Although this conservative approach is accepted commonly for an athlete with symptoms, the 
asymptomatic athlete found to have an abnormal ECG during pre-participation screening 
presents other challenges. Athletes in this situation often have limited time to participate in team 
based tryouts, and sport restriction may jeopardize their athletic eligibility or generate pressure 
from coaches, managers, parents or the athletes themselves. To circumvent some of these 
challenges, proper advanced planning prior to pre-participation screening is required to establish 
avenues for prompt secondary testing and consultation for ECG abnormalities. If ECG is 
included in the cardiovascular screening of athletes, it must be conducted with adequate 
cardiology oversight and resources to assist with the secondary investigation of ECG 
abnormalities. Ideally, pre-participation screening should be performed at a time point that 
permits athletes to undergo additional cardiovascular testing prior to the onset of organized 
competitive athletics. The optimal duration of time between pre-participation screening and the 
beginning of organized team based training will vary as a function of local resources. 
 
Considerations in the Symptomatic Athlete and in the Athlete with a Family History of 
Sudden Death or Hereditary Cardiovascular Disease 
 
Symptoms suggestive of underlying cardiovascular disease including exertional chest 
discomfort, inappropriate exertional dyspnea, unexplained/unheralded syncope, unexplained 
seizure-like activity, and exertional palpitations, particularly when coupled with abnormal ECG 
findings, are strongly suggestive of a pathological process. In the symptomatic athlete either with 
or without an abnormal ECG, comprehensive testing should be tailored to the presenting 
symptoms and performed in a timely fashion. Asymptomatic athletes with a family history of 
sudden death or a heritable cardiomyopathy or ion channelopathy may similarly carry an 
increased risk of true occult disease.161, 162 Great care must be taken to confirm the nature of the 
family history as athletes may have incomplete or erroneous information about their relatives. In 
the evaluation of an athlete with a compelling family history, genetic testing permits a more 
definitive assessment of individual and familial risk for specific disease processes such as HCM, 
ARVC, and congenital LQTS. The use of genetic testing and its interpretation should be 
performed by a cardiovascular specialist with expertise in clinical genetics. 
 
Psychological Considerations of Caring for the Athlete with Potentially Lethal Cardiac 
Disease 
 
Athletes diagnosed with serious cardiac diseases, regardless of the method used for disease 
detection, are at risk for psychological morbidity and represent an emotionally vulnerable 
population.163 Risk factors for increased psychological morbidity include a higher level of 
competition, complete disqualification from athletic competition, daily reminders of disease (i.e. 
medication or implantable cardioverter defibrillator), and unanticipated outcomes (i.e. failed 
cardiac procedure).  
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Informing an athlete that he/she has an underlying cardiac disorder that may affect sports 
participation is difficult. In fact, many athletes may not completely comprehend the nature of 
their disease, and several follow-up discussions are likely necessary. Assessment of emotional 
well-being should be a standard part of all follow-up evaluations, and psychological support for 
the athlete may be enhanced by a multi-disciplinary approach. In cases where competitive sport 
is not recommended, additional measures should consider helping the athlete refocus away from 
athletics, such as excelling in school or becoming involved in other team-related activities (i.e. 
coaching). Athletes disqualified from competitive athletics should be offered exercise 
recommendations thought to be safer to foster long-term physical and mental health. While 
exercise guidelines for individuals with inherited cardiac disorders exist, more research is needed 
to fully understand safe, disease-specific physical activity recommendations.164, 165  
 
CONCLUSION 
 
Accurate ECG interpretation in athletes requires adequate training and an attention to detail to 
distinguish physiological ECG findings from abnormal ECG findings that might indicate the 
presence of cardiac pathology. Cardiac adaptation and remodeling from regular athletic training 
produce common ECG alterations that could be mistaken as abnormal. Whether performed for 
screening or diagnostic purposes, it is critical that physicians responsible for the cardiovascular 
care of athletes be guided by ECG interpretation standards that improve disease detection and 
limit false-positive results. The international consensus standards presented on ECG 
interpretation and the evaluation of ECG abnormalities serve as an important foundation for 
improving the quality of cardiovascular care of athletes. As new scientific data become available, 
revision of these recommendations may be necessary to further advance the accuracy of ECG 
interpretation in the athletic population. 
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FIGURE LEGENDS 
 
Figure 1.  International Consensus Standards for Electrocardiographic Interpretation in Athletes 
 
Figure 2.  ECG of a 29 year old male asymptomatic soccer player showing sinus bradycardia (44 
bpm), early repolarization in I, II, aVF, V2-V6 (arrows), voltage criterion for LVH (S-V1 + R-
V5 > 35 mm), and tall, peaked T waves (circles). These are common, training related findings in 
athletes and do not require more evaluation. 
 
Figure 3. ECG from a patient with HCM demonstrating QRS voltage criterion for LVH in 
association with deep TWI and ST segment depression predominantly in the lateral leads (I, 
aVL, V4-V6), voltage criterion for left atrial and right atrial enlargement, and LAD. 
 
Figure 4.  ECG demonstrates incomplete RBBB with rSR’ pattern in V1 and QRS duration of < 
120 ms. Incomplete RBBB is a common and normal finding in athletes and does not require 
additional evaluation. 
 
Figure 5.  ECG from a black athlete demonstrating voltage criterion for LVH, and convex 
(‘domed’) ST segment elevation followed by TWI in V1-V4 (circles). This is a normal 
repolarization pattern in black athletes. 
 
Figure 6.  Normal and abnormal patterns of TWI. (A) Anterior TWI in V1-V3 in a 12 year old 
asymptomatic athlete without a family history of SCD considered a normal “juvenile” pattern. 
(B) TWI in V1-V4 in a 17 year old asymptomatic mixed race (Middle-Eastern/black) athlete 
without a family history of SCD. This is a normal repolarization pattern in black athletes. (C) 
Biphasic TWI in V3 in a 31 year old asymptomatic black athlete without a family history of 
SCD. Anterior biphasic T waves are considered normal in adolescents < 16 years old and in 
adults when found in a single lead, most commonly V3. (D) Abnormal TWI in V1-V6 in an adult 
symptomatic former soccer player with genetically confirmed ARVC and a positive family 
history of SCD (brother died at 26 years of age). (E) An ECG demonstrating the type 1 Brugada 
pattern with high take-off ST elevation ≥ 2 mm with downsloping ST segment elevation 
followed by a negative symmetric T wave in V1-V2. (F) Inferolateral TWI in leads I, II, III, aVF, 
V2-V6 and ST segment depression in leads II, aVF, V4-V6 in a 31 year old asymptomatic 
professional soccer referee. These markedly abnormal findings require a comprehensive 
evaluation to exclude cardiomyopathy.   
 
Figure 7.  A 28 year old asymptomatic Caucasian handball player demonstrating a junctional 
escape rhythm (red arrows). Note the constant RR interval between beats. 
 
Figure 8.  ECG shows an ectopic atrial rhythm. The atrial rate is 63 beats per minute and the P 
wave morphology is negative in leads II, III, and aVF (arrows), signifying an ectopic atrial 
rhythm. 
 
Figure 9.  ECG shows Mobitz Type I (Wenckebach) 2nd degree AV block demonstrated by 
progressively longer PR intervals until there is a non-conducted P-wave (arrows) and no QRS 
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complex. Note the first PR interval after the dropped beat is shorter than the last conducted PR 
interval prior to the dropped beat. 
 
Figure 10.  ECG from an asymptomatic 22 year old black male athlete demonstrating complete 
RBBB (QRS ≥ 120 ms), LAD (-57°), and RAE (P wave ≥ 2.5 mm in II and aVF). The presence 
of two or more borderline ECG findings warrants additional investigation to exclude pathologic 
cardiac disease.  
 
Figure 11.  ECG from a 30 year old patient with ARVC showing anterior TWI in V1-V3 
preceded by a flat or downsloping ST segment without J-point elevation. PVCs are also present. 
 
Figure 12.  Panel A: ECG from an 18 year old black basketball player demonstrating abnormal 
TWI extending into V5. Initial cardiac imaging was non-diagnostic. Panel B: ECG from the 
same athlete at age 20 showing abnormal TWI in the inferolateral leads with the development of 
deep TWI and ST segment depression in V4-V6. Follow-up cardiac MRI demonstrated distinct 
findings of apical HCM with a maximum left ventricular wall thickness of 21 mm with small 
foci of LGE. Athletes with TWI in V5 and/or V6 require serial evaluation for the development of 
cardiomyopathy. 
 
Figure 13.  Examples of physiological (A) and pathological TWI (B). Panel A demonstrates TWI 
in V1-V4 preceded by convex ‘domed’ ST segment elevation (green circles). This should not be 
confused with pathological TWI (Panel B) which demonstrates TWI in V1-V6 with absent J-
point elevation and a downsloping ST segment (red circles). 
 
Figure 14.  ECG from an 18 year old female swimmer demonstrating deep and wide pathological 
Q waves in V4-V6, I and aVL. Diagnostic testing revealed HCM. 
 
Figure 15.  ECG with complete LBBB demonstrating a QRS ≥ 120 ms, predominantly negative 
QRS complex in lead V1, upright R wave in leads I and V6, and ST segments and T waves in the 
opposite direction of the QRS. LBBB is always an abnormal finding in athletes and warrants a 
comprehensive evaluation to exclude myocardial disease. 
 
Figure 16.  ECG demonstrating the classic findings of WPW pattern with a short PR interval (< 
120 ms), delta wave (slurred QRS upstroke), and prolonged QRS (> 120 ms). 
 
Figure 17.  This figure illustrates the “Teach-the-Tangent” or “Avoid-the-Tail” method for 
manual measurement of the QT interval. A straight line is drawn on the downslope of the T wave 
to the point of intersection with the isoelectric line. The U wave is not included in the 
measurement. 
 
Figure 18.  Brugada type 1 ECG (left) should be distinguished from early repolarization with 
“convex” ST segment elevation in a trained athlete (right). Vertical lines mark the J-point (STJ) 
and the point 80 ms after the J-point (ST80), where the amplitudes of the ST segment elevation 
are calculated. The ‘downsloping’ ST segment elevation in Brugada pattern is characterized by a 
STJ/ST80 ratio > 1. Early repolarization patterns in an athlete show an initial ‘upsloping’ ST 
segment elevation with STJ/ST80 ratio < 1. 
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Figure 19.  ECG from a patient with ARVC.  Note multiple PVCs with a LBBB pattern and 
superior axis (negative QRS vector in inferior leads). 
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Table 1:  International Consensus Standards for Electrocardiographic 
Interpretation in Athletes: Definitions of ECG Criteria  
 
Abnormal ECG findings in athletes 
These ECG findings are unrelated to regular training or expected physiologic adaptation 
to exercise, may suggest the presence of pathologic cardiovascular disease, and require 
further diagnostic investigation. 
ECG abnormality  Definition  
T wave inversion 
 
• Anterior  
 
 
 
 
 
• Lateral 
 
• Inferolateral 
• Inferior 
≥ 1 mm in depth in two or more contiguous leads; 
excludes leads aVR, III, and V1  
• V2-V4  
− excludes: black athletes with J-point 
elevation and convex ST segment 
elevation followed by TWI in V2-V4; 
athletes < age 16 with TWI in V1-V3; and 
biphasic T waves in only V3 
• I and AVL, V5 and/or V6 (only one lead of TWI 
required in V5 or V6) 
• II and aVF, V5-V6, I and AVL  
• II and aVF 
ST segment depression ≥ 0.5 mm in depth in two or more contiguous leads 
Pathologic Q waves Q/R ratio ≥ 0.25 or ≥ 40 ms in duration in two or more 
leads (excluding III and aVR) 
Complete left bundle branch 
block 
QRS ≥ 120 ms, predominantly negative QRS complex in 
lead V1 (QS or rS), and upright notched or slurred R 
wave in leads I and V6 
Profound nonspecific intra-
ventricular conduction delay 
Any QRS duration ≥ 140 ms 
Epsilon wave  Distinct low amplitude signal (small positive deflection 
or notch) between the end of the QRS complex and onset 
of the T wave in leads V1-V3 
Ventricular pre-excitation PR interval < 120 ms with a delta wave (slurred upstroke 
in the QRS complex) and wide QRS (≥ 120 ms) 
Prolonged QT interval* QTc ≥ 470 ms (male) 
QTc ≥ 480 ms (female) 
QTc ≥ 500 ms (marked QT prolongation) 
Brugada Type 1 pattern Coved pattern: initial ST elevation ≥ 2 mm (high take-
off) with downsloping ST segment elevation followed by 
a negative symmetric T wave in ≥ 1 leads in V1-V3 
Profound sinus bradycardia < 30 BPM or sinus pauses ≥ 3 sec 
Profound 1° AV block ≥ 400 ms 
Mobitz type II 2° AV block Intermittently non-conducted P waves with a fixed PR 
interval 
3° AV block Complete heart block 
Atrial tachyarrhythmias Supraventricular tachycardia, atrial fibrillation, atrial 
flutter 
Premature ventricular 
contractions 
≥ 2 PVCs per 10 second tracing 
Ventricular arrhythmias Couplets, triplets, and non-sustained ventricular 
tachycardia  
 
Borderline ECG findings in athletes 
These ECG findings in isolation likely do not represent pathologic cardiovascular 
disease in athletes, but the presence of two or more borderline findings may warrant 
additional investigation until further data become available. 
ECG abnormality Definition   
Left axis deviation  -30° to -90° 
Left atrial enlargement Prolonged P wave duration of > 120 ms in leads I or II 
with negative portion of the P wave ≥ 1 mm in depth and 
≥ 40 ms in duration in lead V1 
Right axis deviation > 120° 
Right atrial enlargement  P wave ≥ 2.5 mm in II, III, or aVF 
Complete right bundle 
branch block 
rSR′ pattern in lead V1 and a S wave wider than R wave 
in lead V6 with QRS duration ≥ 120 ms 
 
Normal ECG findings in athletes 
These training-related ECG alterations are physiologic adaptations to regular exercise, 
considered normal variants in athletes, and do not require further evaluation in 
asymptomatic athletes with no significant family history. 
Normal ECG finding Definition  
Increased QRS voltage Isolated QRS voltage criteria for left  (SV1 + RV5 or 
RV6 > 3.5 mV) or right ventricular hypertrophy (RV1 + 
SV5 or SV6 > 1.1 mV) 
Incomplete RBBB rSR′ pattern in lead V1 and a qRS pattern in lead V6 with 
QRS duration < 120 ms 
Early repolarization J point elevation, ST elevation, J waves, or terminal QRS 
slurring 
Black athlete repolarization 
variant 
J-point elevation and convex (“domed”) ST segment 
elevation followed by T wave inversion in leads V1-V4 
in black athletes  
Juvenile T wave pattern T wave inversion V1-V3 in athletes < age 16 
Sinus bradycardia  ≥ 30 bpm  
Sinus arrhythmia Heart rate variation with respiration: rate increases during 
inspiration and decreases during expiration  
Ectopic atrial rhythm P waves are a different morphology compared to the 
sinus P wave, such as negative P waves in the inferior 
leads (“low atrial rhythm”) 
Junctional escape rhythm QRS rate is faster than the resting P wave or sinus rate 
and typically less than 100 beats/minute with  narrow 
QRS complex unless the baseline QRS is conducted with 
aberrancy    
1° AV block  PR interval 200 ms to 400 ms 
Mobitz Type I (Wenckebach) 
2° AV block 
PR interval progressively lengthens until there is a non-
conducted P wave with no QRS complex; the first PR 
interval after the dropped beat is shorter than the last 
conducted PR interval 
 
* The QT interval corrected for heart rate is ideally measured using Bazett’s formula with 
heart rates between 60-90 bpm; preferably performed manually in lead II or V5 using the 
teach-the-tangent method1 to avoid inclusion of a U wave (please see text for more 
details). Consider repeating the ECG after mild aerobic activity for a heart rate < 50 bpm, 
or repeating the ECG after a longer resting period for a heart rate > 100 bpm, if the QTc 
value is borderline or abnormal. 
 
 
Table 2:  Evaluation of Electrocardiographic Abnormalities 
 
ECG Abnormality Potential Cardiac 
Disease* 
Recommended 
Evaluation** 
Considerations  
T wave inversion 
in the lateral or 
inferolateral leads 
 
HCM 
DCM 
LVNC 
ARVC (with 
predominant LV 
involvement) 
Myocarditis 
 
Echo 
CMR 
Exercise ECG test 
Minimum 24 hour 
ECG monitor 
Lateral or inferolateral T wave 
inversion is common in primary 
myocardial disease. CMR should be a 
routine diagnostic test for this ECG 
phenotype and is superior to 
echocardiography for detecting apical 
HCM, LVH localized to the free 
lateral wall, ARVC with predominant 
left ventricular involvement, and 
myocarditis.    
If CMR is not available, 
echocardiography with contrast should 
be considered as an alternative 
investigation for apical HCM in 
patients with deep T wave inversion in 
leads V5-V6. 
Consider family evaluation if available 
and genetic screening. 
Annual follow-up testing is 
recommended throughout athletic 
career in athletes with normal results.  
T wave inversion 
isolated to the 
inferior leads 
HCM 
DCM 
LVNC 
Myocarditis 
Echo Consider CMR based on echo findings 
or clinical suspicion. 
T wave inversion 
in the anterior 
leads† 
ARVC 
DCM 
Echo 
CMR 
Exercise ECG test 
Minimum 24 hour 
ECG monitor 
SAECG 
The extent of investigations may vary 
based on clinical suspicion for ARVC 
and results from initial testing. 
ST segment 
depression 
HCM 
DCM 
LVNC 
ARVC 
Myocarditis 
Echo Consider CMR and additional testing 
based on echo findings or clinical 
suspicion. 
Pathologic Q 
waves 
HCM 
DCM 
LVNC 
Myocarditis 
Echo 
CAD risk factor 
assessment  
Repeat ECG for 
Consider CMR (with perfusion study 
if available) based on echo findings or 
clinical suspicion.   
In the absence of CMR, consider 
Prior MI septal (V1-V2) QS 
pattern; above 
investigations 
recommended if 
septal Q waves are 
persistent 
exercise stress testing, dobutamine 
stress echocardiogram, or a 
myocardial perfusion scan for 
evaluation of coronary artery disease 
in athletes with suspicion of prior MI 
or multiple risk factors for CAD. 
Complete left 
bundle branch 
block 
DCM 
HCM 
LVNC 
Sarcoidosis 
Myocarditis 
Echo 
CMR (with stress 
perfusion study)^ 
A comprehensive cardiac evaluation to 
rule out myocardial disease should be 
considered.   
Profound 
nonspecific 
intraventricular 
conduction delay ≥ 
140 ms 
DCM 
HCM 
LVNC 
Echo Consider additional testing based on 
echo findings or clinical suspicion. 
Multiple 
premature 
ventricular 
contractions 
HCM 
DCM 
LVNC 
ARVC 
Myocarditis 
Sarcoidosis 
Echo 
24 hour ECG 
monitor 
Exercise ECG test 
If > 2,000 PVC’s or non-sustained 
ventricular tachycardia are present on 
initial testing, comprehensive cardiac 
testing inclusive of CMR is warranted 
to investigate for myocardial disease. 
 
Consider signal averaged ECG 
(SAECG). 
Ventricular pre-
excitation 
WPW  Exercise ECG test 
Echo  
Abrupt cessation of the delta wave 
(pre-excitation) on exercise ECG 
denotes a low risk pathway. 
Electrophysiological study for risk 
assessment should be considered if a 
low risk accessory pathway cannot be 
confirmed by non-invasive testing. 
Consider EP study for moderate to 
high intensity sports. 
Prolonged QTc LQTS Repeat resting ECG 
on separate day 
Review for QT 
prolonging 
medication  
Acquire ECG of 1st 
degree relatives if 
possible 
Consider exercise ECG test, laboratory 
(electrolyte) screening, family 
screening and genetic testing when 
clinical suspicion is high. 
Consider direct referral to a heart 
rhythm specialist or sports cardiologist 
for a QTc ≥ 500 ms. 
Brugada Type 1 
pattern 
Brugada syndrome Referral to 
cardiologist or heart 
rhythm specialist 
Consider high precordial lead ECG 
with leads V1 and V2 in 2nd intercostal 
space or sodium channel blockade if 
Brugada pattern is indeterminate. 
Consider genetic testing and family 
screening. 
Profound sinus 
bradycardia < 30 
BPM 
Myocardial or 
electrical disease 
Repeat ECG after 
mild aerobic 
activity 
Consider additional testing based on 
clinical suspicion. 
Profound 1° AV 
block ≥ 400 ms 
Myocardial or 
electrical disease 
Repeat ECG after 
mild aerobic 
activity 
Exercise ECG test 
Consider additional testing based on 
clinical suspicion. 
Advanced 2° or 3° 
atrioventricular 
block 
Myocardial or 
electrical disease 
Echo 
Minimum 24 hour 
ECG monitor 
Exercise ECG test 
Consider laboratory screening and 
CMR based on echo findings.  
Atrial 
tachyarrhythmias 
Myocardial or 
electrical disease 
Echo 
Minimum 24 hour 
ECG monitor 
Exercise ECG test 
Consider CMR or EP study based on 
clinical suspicion. 
Ventricular 
arrhythmias‡ 
Myocardial or 
electrical disease 
Echo 
CMR 
Minimum 24 hour 
ECG monitor 
Exercise ECG test 
A comprehensive cardiac evaluation to 
rule out myocardial disease and 
primary electrical disease should be 
considered.   
Two or more 
borderline ECG 
findings  
Myocardial disease Echo Consider additional testing based on 
clinical suspicion. 
* This list of disorders for each ECG abnormality represents the primary cardiac disorders of 
concern and is not intended to be exhaustive. 
** Initial evaluation of ECG abnormalities should be performed under the direction of a 
cardiologist. Additional testing will be guided by initial findings and clinical suspicion based on 
the presence of symptoms or a family history of inherited cardiac disease or SCD. 
† Excludes black athlete repolarization variant and juvenile pattern in adolescents ≤ 16 years. 
^ CT coronary angiography if stress perfusion with CMR is unavailable. 
‡ Includes couplets, triplets, accelerated ventricular rhythm, and non-sustained ventricular 
tachycardia. 
Normal ECG Findings
• Increased QRS voltage for 
LVH or RVH
• Incomplete RBBB
• Early repolarization/ST 
segment elevation
• ST elevation followed by T 
wave inversion V1-V4 in 
black athletes
• T wave inversion V1-V3 ≤ 
age 16 years old
• Sinus bradycardia or 
arrhythmia
• Ectopic atrial or junctional 
rhythm
• 1° AV block
• Mobitz Type I 2° AV block
Borderline ECG Findings
• Left axis deviation
• Left atrial enlargement
• Right axis deviation
• Right atrial enlargement
• Complete RBBB
Abnormal ECG Findings
• T wave inversion 
• ST segment depression
• Pathologic Q waves
• Complete LBBB
• QRS ≥ 140 ms duration
• Epsilon waves
• Ventricular pre-excitation
• Prolonged QT interval
• Brugada Type 1 pattern
• Profound sinus bradycardia 
< 30 bpm
• PR interval ≥ 400 ms
• Mobitz Type II 2° AV block
• 3° AV block
• ≥ 2  PVCs
• Atrial tachyarrhythmias
• Ventricular arrhythmias
No further evaluation required 
in asymptomatic athletes with no 
family history of inherited cardiac 
disease or SCD
Further evaluation required 
to investigate for pathologic 
cardiovascular disorders associated 
with SCD in athletes
2 or moreIn isolation
>35mm
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